Compare ELVN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVN | TVTX |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.7B |
| IPO Year | 2020 | 2013 |
| Metric | ELVN | TVTX |
|---|---|---|
| Price | $46.48 | $46.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $74.33 | $73.43 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.17 | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.96 |
| Revenue Next Year | N/A | $48.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $22.59 |
| 52 Week High | $62.32 | $68.73 |
| Indicator | ELVN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 35.71 |
| Support Level | $44.18 | $41.75 |
| Resistance Level | $46.96 | $48.60 |
| Average True Range (ATR) | 2.47 | 2.55 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 25.69 | 29.52 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.